Gliomas are malignant tumors and are the most common malignant tumors in the cranial brain, accounting for 40%-50% of overall cranial brain tumors. Glioma is a tumor of neuroepithelial origin, and it grows in the same way as malignant tumors, from the unrestricted differentiation and growth of some cells that encroach on surrounding tissues and organs, causing various clinical symptoms. The most prominent manifestation is the continuous invasion of the surrounding tissues, which makes it difficult to be completely removed and there are often residual cases, so the tumor often recurs after surgery. In layman’s terms, it is like a weed that cannot be destroyed by fire and grows again by spring breeze. Currently, there are many grading and staging systems for glioma, but the most common one is the World Health Organization (WHO) grading system, which is 1-2, that is, the most commonly referred to as low-grade glioma, which is relatively a well-differentiated glioma, but also a kind of malignant tumor. The prognosis is relatively good, but the end-stage prognosis is not good either. High-grade glioma, which is classified as grade 3-4 in WHO, is a low-differentiated glioma, which is a malignant tumor with poor prognosis.